Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Iphigénie Korakis
Observed names:
I. Korakis,
Iphig nie Korakis,
Iphigenia Korakis,
Iphigenie Korakis,
Korakis Iphigenie
Institutions:
Institut universitaire du cancer de Toulouse Oncopole,
Institut Claudius Regaud,
Université de Toulouse
Observed institutions:
Institut universitaire du cancer de Toulouse Oncopole,
Institut Claudius Regaud,
Université de Toulouse,
German University in Cairo
ORCID:
0000-0002-2112-5932
Observed ORCID:
0000-0002-2112-5932
OpenAlex ID:
A5020724418
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
2024
·
Aurélien Voissière
, Carlos Gomez-Roca
, et al.
·
Science Translational Medicine
·
80
PDF
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
2022
·
Sophie Cousin
, Coralie Cantarel
, et al.
·
European Journal of Cancer
·
59
PDF
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending
2019
·
Ariadna Ortiz Brugués
, Vincent Sibaud
, et al.
·
The Oncologist
·
41
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
2021
·
Stéphane Champiat
, Philippe A. Cassier
, et al.
·
Journal of Clinical Oncology
·
29
Improving patient selection for immuno‐oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center
2020
·
Ghassan Al Darazi
, Elodie Martin
, et al.
·
International Journal of Cancer
·
17
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
2024
·
Hyun Cheol Chung
, Esma Saada‐Bouzid
, et al.
·
Cancer
·
16
PDF
983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
2021
·
N. Kotecki
, S. Champiat
, et al.
·
Annals of Oncology
·
15
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
2022
·
Elena Garralda
, Aung Naing
, et al.
·
Journal of Clinical Oncology
·
13
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis
2025
·
Sophie Cousin
, Jean-Philippe Guégan
, et al.
·
Nature Cancer
·
12
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
2022
·
Yann‐Alexandre Vano
, Letuan Phan
, et al.
·
International Journal of Cancer
·
11
PDF
A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours
2019
·
Jean-Pierre Delord
, Nuria Kotecki
, et al.
·
Blood
·
11
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
2026
·
Neeltje Steeghs
, Carlos Gomez-Roca
, et al.
·
Nature Cancer
·
10
PDF
Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.
2021
·
Sophie Cousin
, Carine A. Bellera
, et al.
·
Journal of Clinical Oncology
·
10
612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
2024
·
M. Vieito
, M. Mckean
, et al.
·
Annals of Oncology
·
8
PDF
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
2024
·
Neeltje Steeghs
, Carlos A. Gomez-Roca
, et al.
·
Journal of Clinical Oncology
·
8
2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, advanced solid tumors: Phase I/Ib trial
2025
·
K. Shitara
, H.J. Choi
, et al.
·
Annals of Oncology
·
7
PDF
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
2025
·
Stephane Champiat
, Elena Garralda
, et al.
·
Cell Reports Medicine
·
6
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review
2024
·
François Poumeaud
, Marion Jaffrelot
, et al.
·
Frontiers in Medicine
·
4
1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort
2023
·
S. Cousin
, C. Bellera
, et al.
·
Annals of Oncology
·
4
PDF
EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.
2026
·
Fiona Thistlethwaite
, Desamparados Roda
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
2026
·
Denis Lacombe
, Fábio Cardoso Borges
, et al.
·
Journal of Cancer Policy
·
3
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement
2025
·
I. Korakis
, K. Ouali
, et al.
·
ESMO Open
·
3
PDF
Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial
2022
·
Stephane Champiat
, Aurelien Marabelle
, et al.
·
Cancer Research
·
3
162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours
2019
·
A. Marabelle
, P. Cassier
, et al.
·
Annals of Oncology
·
3
Abstract 3276: Clinical PK, PD and safety analysis of a phase I clinical trial of DT-9081, an EP4R-antagonist, for RP2D determination in patients with advanced solid tumours
2025
·
Christophe Le Tourneau
, Zahra Castel-Ajgal
, et al.
·
Cancer Research
·
2
Show more works
View as search
Works count:
52
Citation count:
390
H-index:
11
I10-index:
13
Year
Topic
Type